Presage Biosciences raises $6M from Takeda and Celgene, names Rich Klinghoffer CEO to scale CIVO tumor microdosing platform
Presage Biosciences raised $6 million led by Takeda and Celgene to expand use of its CIVO platform, which microdoses cancer drugs into human tumors to speed early testing, and appointed Rich Klinghoffer as CEO while founder Nathan Caffo becomes a strategic advisor.